Team Member
Kim joined the Vivli team in 2021 as Administrative Coordinator and currently works as Manager of Administration, where she is responsible for supporting members in their day-to-day operations.
Prior to joining Vivli, Kim worked with a commercial real estate firm as an Executive Assistant, supporting a team of brokers and developing standard operating procedures. Kim holds an Associate of Science degree in Public Health.
Zeina Attar is a Senior Program Manager at Vivli, where she leads strategic alignment and governance efforts to support operational excellence and sustainable growth. She brings over 15 years of experience driving complex, cross-functional initiatives across health, research, and regulatory domains.
Before joining Vivli, Zeina held program leadership roles at the National Institutes of Health, where she managed high-impact initiatives for the All of Us Research Program—advancing precision medicine through improved data transparency and delivery. Prior to that, she spent a decade at 3E, managing regulatory SaaS implementations and global compliance projects for organizations such as the European Chemicals Agency.
Zeina is a certified Project Management Professional (PMP) and holds a Lean Six Sigma Green Belt. She is passionate about building high-performing teams, strengthening program delivery frameworks, and driving mission-aligned impact through data and collaboration.
Amrutha Baskaran serves as the Product Director at Vivli. She received a MD from Tbilisi State Medical University, Republic of Georgia and a master’s degree in Clinical Research from the Medical University of South Carolina (MUSC). In addition, she completed a Fellowship in Clinical Research Ethics from the South Carolina Clinical and Translational Institute at MUSC.
Prior to the current position Amrutha worked as a Clinical Trial Lead for a medical device company running clinical trials on aortic stent grafts. She has 6 years of clinical trials experience in both academia and industry setting. She has experience in various roles as the study lead, data manager and regulatory specialist which gave her the exposure of working on both national and global clinical trials. In the past, Amrutha served as an Institutional Review Board member at the University of California, San Diego and as an external reviewer for Clinical Research Ethics Consultation Services at MUSC.
Prior to joining Vivli, Elizabeth was an Architect at Insight, Inc., a Vivli development partner. At Insight, Elizabeth was one of the first developers for the Vivli platform, joining the project at its kickoff in 2017 and continuing to work on Vivli for much of the next 7 years. She played a key role in translating complex business requirements into an effective implementation, and became known as the development team’s domain expert. Her other Insight experience included a number of Azure-based projects in the healthcare and life sciences vertical, working as a full stack developer with design responsibility for numerous Web APIs. Prior to Insight, Elizabeth worked in the medical device industry, building native applications for computer-assisted medical devices, with responsibility for all application development, maintenance, and software-related regulatory support.
Catherine D’Arcy is the Associate Director of Operations for Vivli. Prior to joining Vivli, Catherine gained 30 years of experience in the pharmaceutical industry, most recently managing data sharing requests for GlaxoSmithKline, and prior to that within clinical trial operations. She has a bachelor degree in Medical Biochemistry from the University of London.
Rylie Garrison, MEd is the Grants and Finance Administrator of Vivli. She also serves as Senior Grants Administrator in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. In this position, she oversees finance and compliance for approximately 150 research grants from a variety of federal and philanthropic sponsors. She received her MEd in Higher Education Administration in 2019.
Rebecca Li, PhD, is the CEO of Vivli and on faculty at the Center for Bioethics at the Harvard Medical School. Previous to her current role she was the Executive Director of the MRCT Center of Brigham and Women’s Hospital and Harvard for over 5 years and remains a Senior Advisor at the Center. She has over 25 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. She completed a Fellowship in 2013 in the Division of Medical Ethics at Harvard Medical School. She earned her PhD in Chemical and Biomolecular Engineering from Johns Hopkins University.
Director of Microbiology at Paratek Pharmaceuticals with over 20 years of experience in antibacterial research and development.
I received a B.S. in Medical Technology from Northeastern University and began my career as a Medical Technologist working in the clinical microbiology laboratory for several years before transitioning to the pharmaceutical industry. Prior to joining Paratek, I spent 13 years with Cubist Pharmaceuticals, developing Cubicin and Zerbaxa.
My primary areas of responsibility include, leading the Paratek Keystone Surveillance Program, managing antimicrobial susceptibility testing development, clinical trial development and writing support of regulatory submissions.
I am a member of the American Society of Microbiology and Infectious Disease Society of America.
Patricia A. Bradford is the owner of Antimicrobial Development Specialists LLC, a consulting company that focuses on the late-stage development of antibiotics. Prior to this she was at AstraZeneca and was responsible for the microbiology support contributing to the successful development and approval of ceftazidime-avibactam. Before joining AstraZeneca, Dr. Bradford worked in antibiotic research for Novartis, Wyeth Pharmaceuticals and Lederle Laboratories. During her tenure at Wyeth she worked on a number of antibiotic projects and was instrumental in the team that wrote the dossier for the registration and approval of tigecycline. She was also heavily involved in the studies for several sNDA applications for piperacillin-tazobactam.
Dr. Bradford is fellow in the American Academy of Microbiology, has over 100 publications in peer-reviewed scientific journals and has written several review articles and book chapters. She served as an editor for Antimicrobial Agents Chemotherapy 2001-2011 and is currently a Senior Editor for ASM’s newest journal, mSphere. She is also an active participant with the subcommittee on Antimicrobial Susceptibility Testing of the Clinical Laboratory Standards Institute.
Prior to working industry, she worked as a clinical microbiologist at Nebraska Methodist Hospital in Omaha. Dr. Bradford received a B.S. in Medical Technology from the University of Nebraska Medical Center, Ph.D. in Medical Microbiology from Creighton University and completed a post-doctoral fellowship in β-lactamase research.
Ana Cristina Gales is a Professor in the Division of Infectious Diseases at Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM-UNIFESP). She also serves as the Director of the Laboratory Alerta in São Paulo, Brazil.
Dr. Gales earned her medical degree from the Faculdade de Medicina (FMABC) in 1991 and completed her residency in Internal Medicine and Infectious Diseases at EPM-UNIFESP from 1992 to 1995. She obtained a PhD in health sciences from EPM-UNIFESP in 2001, following a research fellowship in medical microbiology at the University of Iowa’s Department of Pathology in Iowa City, USA (1998-2000).
Her research focuses on the molecular epidemiology of multidrug-resistant bacteria and the in vitro activity of new antimicrobials. Dr. Gales is a full member of the Technical Chamber on Microbial Resistance in Health Services (CATREM), advising the Brazilian Health Regulatory Agency (Anvisa) on standards and measures for monitoring, controlling, and preventing antimicrobial resistance in Brazilian health services. She is also the Vice-Coordinator of the newly established Antimicrobial Resistance Institute of São Paulo (Aries).
She has collaborated on several global programs monitoring antimicrobial resistance rates and phenotypes among clinically relevant pathogens. She served as Chair of the Brazilian Committee on Antimicrobial Susceptibility (BrCAST) from 2017 to 2018. Additionally, she is an editor for The Brazilian Journal of Infectious Diseases and the Journal of Global Antimicrobial Resistance and has been a distinguished member of the Scientific Advisory Committee of the Global Antibiotic R&D Partnership (GARDP) since July 2021.